RARRES2 Regulates Lipid Metabolic Reprogramming to Mediate the Development of Brain Metastasis in Triple Negative Breast Cancer

Overview

Journal Mil Med Res

Publisher Biomed Central

Specialty Emergency Medicine

Date 2023 Jul 25

PMID 37491281

Authors

Yi-Qun Li

Fang-Zhou Sun

Chun-Xiao Li

Hong-Nan Mo

Yan-Tong Zhou

Dan Lv

Jing-Tong Zhai

Hai-Li Qian

Fei Ma

Affiliations

Soon will be listed here.

Abstract

Background: Triple negative breast cancer (TNBC), the most aggressive subtype of breast cancer, is characterized by a high incidence of brain metastasis (BrM) and a poor prognosis. As the most lethal form of breast cancer, BrM remains a major clinical challenge due to its rising incidence and lack of effective treatment strategies. Recent evidence suggested a potential role of lipid metabolic reprogramming in breast cancer brain metastasis (BCBrM), but the underlying mechanisms are far from being fully elucidated.

Methods: Through analysis of BCBrM transcriptome data from mice and patients, and immunohistochemical validation on patient tissues, we identified and verified the specific down-regulation of retinoic acid receptor responder 2 (RARRES2), a multifunctional adipokine and chemokine, in BrM of TNBC. We investigated the effect of aberrant RARRES2 expression of BrM in both in vitro and in vivo studies. Key signaling pathway components were evaluated using multi-omics approaches. Lipidomics were performed to elucidate the regulation of lipid metabolic reprogramming of RARRES2.

Results: We found that down-regulation of RARRES2 is specifically associated with BCBrM, and that RARRES2 deficiency promoted BCBrM through lipid metabolic reprogramming. Mechanistically, reduced expression of RARRES2 in brain metastatic potential TNBC cells resulted in increased levels of glycerophospholipid and decreased levels of triacylglycerols by regulating phosphatase and tensin homologue (PTEN)-mammalian target of rapamycin (mTOR)-sterol regulatory element-binding protein 1 (SREBP1) signaling pathway to facilitate the survival of breast cancer cells in the unique brain microenvironment.

Conclusions: Our work uncovers an essential role of RARRES2 in linking lipid metabolic reprogramming and the development of BrM. RARRES2-dependent metabolic functions may serve as potential biomarkers or therapeutic targets for BCBrM.

Citing Articles

Integrated bulk and single-cell transcriptomic analysis unveiled a novel cuproptosis-related lipid metabolism gene molecular pattern and a risk index for predicting prognosis and antitumor drug sensitivity in breast cancer.

Zeng C, Xu C, Liu S, Wang Y, Wei Y, Qi Y Discov Oncol. 2025; 16(1):318.

PMID: 40085377 DOI: 10.1007/s12672-025-02044-x.

Single-cell RNA transcriptome uncovers distinct developmental trajectories in the embryonic skeletal muscle of Daheng broiler and Tibetan chicken.

Li J, Yang D, Chen C, Wang J, Wang Z, Yang C BMC Genomics. 2025; 26(1):187.

PMID: 39994525 PMC: 11854108. DOI: 10.1186/s12864-025-11363-w.

Comprehensive analysis of lipid metabolic signatures identified CEBPD promotes breast cancer cell proliferation.

Zhao Y, He H, Huang L, Yu L Sci Rep. 2025; 15(1):6570.

PMID: 39994306 PMC: 11850814. DOI: 10.1038/s41598-025-90869-5.

GABA regulates metabolic reprogramming to mediate the development of brain metastasis in non-small cell lung cancer.

Xie M, Qin H, Liu L, Wu J, Zhao Z, Zhao Y J Exp Clin Cancer Res. 2025; 44(1):61.

PMID: 39972344 PMC: 11837350. DOI: 10.1186/s13046-025-03315-9.

UBE2T/CDC42/CD276 signaling axis mediates brain metastasis of triple-negative breast cancer via lysosomal autophagy.

Shi L, Chen Y, Xie M, Chen Q, Qiao X, Cheng Q J Immunother Cancer. 2025; 13(2).

PMID: 39915000 PMC: 11804199. DOI: 10.1136/jitc-2024-010782.

References

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Lin N, R Bellon J, Winer E . CNS metastases in breast cancer. J Clin Oncol. 2004; 22(17):3608-17. DOI: 10.1200/JCO.2004.01.175. View

Lin N, Vanderplas A, Hughes M, Theriault R, Edge S, Wong Y . Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012; 118(22):5463-72. PMC: 3611659. DOI: 10.1002/cncr.27581. View

Boire A, Brastianos P, Garzia L, Valiente M . Brain metastasis. Nat Rev Cancer. 2019; 20(1):4-11. DOI: 10.1038/s41568-019-0220-y. View

Sirhan Z, Thyagarajan A, Sahu R . The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer. Mil Med Res. 2022; 9(1):39. PMC: 9277867. DOI: 10.1186/s40779-022-00401-3. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Currie E, Schulze A, Zechner R, Walther T, Farese Jr R . Cellular fatty acid metabolism and cancer. Cell Metab. 2013; 18(2):153-61. PMC: 3742569. DOI: 10.1016/j.cmet.2013.05.017. View

Jin X, Demere Z, Nair K, Ali A, Ferraro G, Natoli T . A metastasis map of human cancer cell lines. Nature. 2020; 588(7837):331-336. PMC: 8439149. DOI: 10.1038/s41586-020-2969-2. View

Ferraro G, Ali A, Luengo A, Kodack D, Deik A, Abbott K . FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS. Nat Cancer. 2021; 2(4):414-428. PMC: 8223728. DOI: 10.1038/s43018-021-00183-y. View

10.

Zou Y, Watters A, Cheng N, Perry C, Xu K, Alicea G . Polyunsaturated Fatty Acids from Astrocytes Activate PPARγ Signaling in Cancer Cells to Promote Brain Metastasis. Cancer Discov. 2019; 9(12):1720-1735. PMC: 6891206. DOI: 10.1158/2159-8290.CD-19-0270. View

11.

Ernst M, Sinal C . Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010; 21(11):660-7. DOI: 10.1016/j.tem.2010.08.001. View

12.

Goralski K, McCarthy T, Hanniman E, Zabel B, Butcher E, Parlee S . Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007; 282(38):28175-88. DOI: 10.1074/jbc.M700793200. View

13.

Li J, Yin H, Guan D, Zhao J, Feng Y, Deng Y . Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis. Br J Cancer. 2018; 118(10):1337-1348. PMC: 5959946. DOI: 10.1038/s41416-018-0077-y. View

14.

Pachynski R, Zabel B, Kohrt H, Tejeda N, Monnier J, Swanson C . The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. J Exp Med. 2012; 209(8):1427-35. PMC: 3409495. DOI: 10.1084/jem.20112124. View

15.

Shin W, Zabel B, Pachynski R . Mechanisms and Functions of Chemerin in Cancer: Potential Roles in Therapeutic Intervention. Front Immunol. 2018; 9:2772. PMC: 6283908. DOI: 10.3389/fimmu.2018.02772. View

16.

Butler A, Hoffman P, Smibert P, Papalexi E, Satija R . Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018; 36(5):411-420. PMC: 6700744. DOI: 10.1038/nbt.4096. View

17.

Gonzalez H, Mei W, Robles I, Hagerling C, Allen B, Okholm T . Cellular architecture of human brain metastases. Cell. 2022; 185(4):729-745.e20. PMC: 8857062. DOI: 10.1016/j.cell.2021.12.043. View

18.

Su M, Pan T, Chen Q, Zhou W, Gong Y, Xu G . Data analysis guidelines for single-cell RNA-seq in biomedical studies and clinical applications. Mil Med Res. 2022; 9(1):68. PMC: 9716519. DOI: 10.1186/s40779-022-00434-8. View

19.

Vareslija D, Priedigkeit N, Fagan A, Purcell S, Cosgrove N, OHalloran P . Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. J Natl Cancer Inst. 2018; 111(4):388-398. PMC: 6449168. DOI: 10.1093/jnci/djy110. View

20.

Fidler I . The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3(6):453-8. DOI: 10.1038/nrc1098. View